Public health labs have handled most testing thus far for the Texas and New Mexico outbreaks, but commercial labs are ...

NEW YORK — Tasso has struck a deal to offer its blood-collection devices in Japan through a new joint venture with Tokyo-based drug development services provider Shin Nippon Biomedical Laboratories, ...

The firm's next-generation pancreatic cancer test looks for five biomarkers that are indicative of early-stage disease.

The company presented its results this week at a conference and anticipates that with additional validation early next year, it will be ready to file for regulatory approval.

The firm will develop an assay to detect and monitor Pseudomonas aeruginosa infection in patients with cystic fibrosis.

NEW YORK – Invivoscribe announced Thursday that its test for FLT3 mutations in patients with leukemia has achieved regulatory compliance in the UK and Switzerland.

The test can be used to better stratify cancer patients and determine the likelihood of breast cancer metastasizing.

Proceeds from the offering will be used for research and continued product development, clinical studies, and product commercialization.

Justin Hanson operated a kickback scheme in which he paid the owner of a Milwaukee substance abuse treatment clinic kickbacks for urine drug testing referrals.

The company will use the money to advance the development and commercialization of its liquid biopsy cancer detection panels.

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

The precision cancer business of PHC Holdings anticipates an increase in cancer cases and is expanding its digital pathology and immunohistochemistry instrument lineup.